Publicly reported negotiated prices under the Medicare Drug Price Negotiation Program provide drug-level information, but viewing each product in isolation makes it difficult to see broader patterns across…

For primary immunodeficiency and inborn errors of immunity, recurrent infections are only one part of the burden. Delayed recognition, repeated healthcare use before diagnosis, access to genetic testing…

Number needed to treat is frequently used to translate treatment effects into an intuitive decision metric, but the calculation is only meaningful when it matches the structure of…

Managed-entry agreements are used when a promising health technology reaches reimbursement decision-making with unresolved financial, clinical, or implementation uncertainty. Across jurisdictions, however, these arrangements are described and implemented…

Number needed to treat is intuitive when the outcome is binary. It expresses how many patients must be treated to prevent one additional event. Recurrent outcomes such as…